FDA approves Pfizer’s COVID-19 vaccine booster for young kids

The regulatory bodies’ authorization now offers a third shot to elementary kids aged 5-11.

The U.S. Food and Drug Administration (FDA) approved the use of a booster dose of Pfizer and BioNTech's COVID-19 vaccine for children aged 5 to 11, allowing anyone above the age of 5 to receive a third shot. Before the shots may be administered out, the United States Centers for Disease Control and Prevention (CDC) must approve them. In the U.S., children under the age of five are not yet eligible for the COVID-19 vaccine. In the face of research suggesting that vaccine immunity wanes over time, the U.S. government has been pushing for eligible Americans to get boosters, and it just authorized a second shot for people 50 and older. A first booster dose was given to approximately 102.3 million people.

According to FDA Commissioner Robert Califf, the new authorization is intended to give continuing protection against COVID-19 for children aged 5 to 11. It is uncertain how many parents will opt for a third dose for their children in that age group. According to CDC data, just 28.8% of children aged 5 to 11 are fully vaccinated. Out of all the groups, this has the lowest vaccination coverage. Booster vaccinations in this age group, according to Dr. Paul Offit of Children's Hospital of Philadelphia, would have a minimal influence on the pandemic, despite evidence that the additional shots will protect against moderate sickness for three to six months. On Thursday, the CDC will hold a conference of outside advisers to consider vaccine boosters.